

Lluís Cecchini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6641431/publications.pdf>

Version: 2024-02-01

7
papers

83
citations

1683934
5
h-index

1719901
7
g-index

7
all docs

7
docs citations

7
times ranked

156
citing authors

#	ARTICLE	IF	CITATIONS
1	SPOP and <i>CHD1</i> alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. <i>Prostate</i> , 2021, 81, 1267-1277.	1.2	7
2	Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 223-231.	1.4	18
3	SPOP and FOXA1 mutations are associated with PSA recurrence in ERGwt tumors, and SPOP downregulation with ERG rearranged prostate cancer. <i>Prostate</i> , 2019, 79, 1156-1165.	1.2	12
4	Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 457-466.	1.4	5
5	Micronuclei frequency in urothelial cells of bladder cancer patients, as a biomarker of prognosis. <i>Environmental and Molecular Mutagenesis</i> , 2019, 60, 168-173.	0.9	10
6	ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression. <i>Oncotarget</i> , 2017, 8, 74106-74118.	0.8	16
7	Concurrent <i>TMPRSS2-ERG</i> and <i>SLC45A3-ERG</i> rearrangements plus <i>PTEN</i> loss are not found in low grade prostate cancer and define an aggressive tumor subset. <i>Prostate</i> , 2016, 76, 854-865.	1.2	15